Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation.

× No keyword cloud information.

72 in total

Review 1. Melanoma: from mutations to medicine.

Authors: Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal: Genes Dev Date: 2012-06-01 Impact factor: 11.361

Review 2. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.

Authors: Scott E Woodman; Michael A Davies
Journal: Biochem Pharmacol Date: 2010-05-08 Impact factor: 5.858

Review 3. Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges.

Authors: Laura E MacConaill; Paul Van Hummelen; Matthew Meyerson; William C Hahn
Journal: Cancer Discov Date: 2011-09 Impact factor: 39.397

4. Activity of Imatinib Mesylate in Metastatic Anorectal Melanoma: A Case Report.

Authors: Samia Arifi; El Mehdi Tazi; Omar El Mesbahi; Hassan Errihani
Journal: J Gastrointest Cancer Date: 2012-09

Review 5. From genes to drugs: targeted strategies for melanoma.

Authors: Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal: Nat Rev Cancer Date: 2012-04-05 Impact factor: 60.716

Review 6. A brief history of melanoma: from mummies to mutations.

Authors: Vito W Rebecca; Vernon K Sondak; Keiran S M Smalley
Journal: Melanoma Res Date: 2012-04 Impact factor: 3.599

Review 7. Molecular targets in melanoma: time for 'ethnic personalization'.

Authors: Shane Y Morita; Svetomir N Markovic
Journal: Expert Rev Anticancer Ther Date: 2012-05 Impact factor: 4.512

8. Copy number gains in 11q13 and 8q24 [corrected] are highly linked to prognosis in cutaneous malignant melanoma.

Authors: Pedram Gerami; Susan S Jewell; Pedram Pouryazdanparast; Jeffery D Wayne; Zahra Haghighat; Klaus J Busam; Alfred Rademaker; Larry Morrison
Journal: J Mol Diagn Date: 2011-05 Impact factor: 5.568

Review 9. Clinical implications of the cancer genome.

Authors: Laura E Macconaill; Levi A Garraway
Journal: J Clin Oncol Date: 2010-10-25 Impact factor: 44.544

10. A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.

Authors: Maryline Allegra; Damien Giacchero; Coralie Segalen; Nicolas Dumaz; Catherine Butori; Véronique Hofman; Paul Hofman; Jean-Philippe Lacour; Corine Bertolotto; Philippe Bahadoran; Robert Ballotti
Journal: J Invest Dermatol Date: 2013-12-06 Impact factor: 8.551